Background
Capillary malformation, usually referred to as a port-wine stain or nevus flammeus, is the most common type of vascular malformation. As a congenital malformation of the superficial dermal blood vessels, capillary malformation is present at birth and grows in size commensurate with the child; capillary malformations remain present for life and have no tendency toward involution. A rare form of capillary malformation that is not present at birth is referred to as an acquired capillary malformation; however, this article focuses on the more common congenital lesion.
Past nosology of this lesion has resulted in much confusion, and an excessive number of descriptive terms have been applied to it. Confusion originated from difficulty in differentiating vascular malformations from vascular proliferative lesions, such as hemangiomas, and from the use of wholly clinical descriptions in categorizing these lesions. Vascular malformations are categorized by predominate vessel type, such as arterial, venous, lymphatic, capillary, or complex (a combination of different vessels).
Although some capillary malformations may be associated with other vessel malformations, most occur alone as venulocapillary malformations. In 2008, Happle argued that the term capillary malformation should be used as a more generalized designation for several congenital disorders of dilated capillaries (eg, angiokeratomas, nevus anemicus, cutis marmorata telangiectatica congenita).[1] While this notion has merit, the accepted nomenclature is that capillary malformation be reserved for a patch of red-colored skin, historically referred to as a port-wine stain or a nevus flammeus.
Pathophysiology
Capillary malformations and other vascular malformations are the result of abnormal morphogenesis. Capillary malformations are characterized by ectatic papillary dermal capillaries and postcapillary venules in the upper reticular dermis, with some evidence of increased vessel density and no apparent proliferation of vessels. These ectatic vessels are lined by flat, benign-appearing endothelial cells, similar to the vessels of normal skin, with similar staining characteristics for endothelial antigens, including fibronectin, von Willebrand factor, and collagenous basement membrane proteins. The endothelial cells also exhibit cell turnover similar to normal vessels, supported by a paucity of mitoses or an uptake of tritiated thymidine. One study demonstrated a mean vessel depth of 0.46 mm in capillary malformations, suggesting that most of the vessels are superficial.
Evidence supports a neural role in both the development and progression of capillary malformations. Animal studies show that the sympathetic nervous system influences the composition and functional properties of the vessel wall during development.
Immunohistochemical studies of capillary malformations reveal a significantly decreased density of perivascular nervous tissue in lesional skin, suggesting that inadequate innervation may be responsible for decreased vascular tone and progressive vascular dilatation.[2] Confocal microscopic studies demonstrate an inverse correlation between nerve density and blood vessel diameter and evidence that capillary malformations with the lowest nerve density exhibit the highest blood vessel density and the poorest response to laser intervention.[3] The finding of increased vessel diameter and/or decreased nerve density may be secondary to other factors, such as local cytokine production or abnormal receptors; however, this has not been elucidated.
The potent endothelial cell mitogen vascular endothelial growth factor (VEGF)–A and its most active receptor VEGF-R2 expression are significantly increased in capillary malformation skin tissue compared with control skin.[4] This may suggest that VEGF and VEGF-R could contribute to the pathogenesis of capillary malformations by inducing vessel proliferation and/or vasodilatation. If this is indeed a pathogenic factor, antiangiogenic treatments using VEGF blocking agents may prove to be useful for capillary malformations. Conversely, one report describes expansion of a biopsy-proven capillary malformation following partial surgical excision in an adult in whom the newly expanded capillary malformation expressed marked elevations of both tyrosine kinase receptor (Tie2) and its ligand angiopoietin-1 and no increase in VEGF.[5] Tie2 and angiopoietin-1 are known regulators of vascular remodeling during angiogenesis, mutations of which have been demonstrated in familial venous malformations.
An inactivating mutation of RASA1 on 5q has been detected in some kindreds with multiple, small, round-to-oval, pink capillary malformations.[6] RASA1 encodes a GTPase-activating protein, which negatively regulates Ras activity. These kindreds all had members who also had arteriovenous malformations (AVMs) or arteriovenous fistulae (AVFs). This disease has been coined capillary malformation-AVM syndrome to denote the 2 types of vascular malformations observed in these kindreds. One kindred with a novel RASA1 -inactivating mutation included a member with a large lower extremity capillary malformation with associated ipsilateral limb enlargement[7] ; however, another large kindred has been identified that has only capillary malformations and no evidence of AVMs or AVFs, suggesting that RASA1 mutations may be implicated more often than previously believed.[8]
Use of transcutaneous videomicroscopy and handheld dermoscopy reveals 2 distinct patterns of vascular ectasia in capillary malformations. The type 1 abnormality is composed of superficial, tortuous, dilated end-capillary loops in the superficial papillary dermis. The type 2 abnormality consists of dilated, ectatic vessels in the superficial horizontal vascular plexus. Some patients exhibit a combination of both abnormal patterns. Evidence suggests that the type 1 abnormality has a better response to 585-nm flashlamp-pumped pulsed-dye laser (PDL) therapy than the type 2 abnormality.[9] Moreover, one study found a correlation between the depth and pattern of the capillary malformations and the location of the lesions, demonstrating improved responses to laser therapy with locations demonstrating a type 1 pattern (V3 region of the face, neck, and trunk).
Epidemiology
Frequency
United States
Capillary malformation occurs in 0.3-0.5% of newborns.
International
Worldwide, capillary malformation occurs in 0.1-2% of newborns.
Mortality/Morbidity
- Isolated capillary malformations do not appear to cause an increase in mortality; however, psychosocial disability secondary to facial disfigurement can be overwhelming. Several studies demonstrate that patients with facial capillary malformations exhibit greater self-concern, ruminative self-doubt in interpersonal interactions, social inhibition, isolated and passive orientation in interpersonal relationships, stigmatization from society, and limitations of privileges and opportunities otherwise afforded to those without facial disfigurement. One study demonstrated that the psychosocial difficulties not only persisted but actually worsened in adulthood.[10]
- Development of lobulated capillary hemangiomas (pyogenic granulomas) overlying capillary malformations often results in bleeding.[11, 12] The destruction of these lesions usually results in minor scarring of the skin.
- Any morbidity involved with capillary malformations is associated with more extensive vascular malformations.
Race
According to at least one survey, capillary malformations are more common in whites than in African Americans.[13]
Sex
The sex distribution of capillary malformations is equal.
Age
Capillary malformations are present at birth. Some lesions may not be readily observed at birth because of anemia or plethora. In certain lesions, some lightening of the lesions may occur during the first year of life; however, beyond that time, further lightening is generally not observed.
The very rare acquired port-wine stain can occur at any age after birth and is identical to congenital capillary malformations both clinically and histologically. The etiology of these lesions is unknown and most are idiopathic; however, trauma, chronic UV exposure, hormonal influences, infections, solid brain tumor, and various internal vascular disorders have been implicated.[14]
Happle R. What is a capillary malformation?. J Am Acad Dermatol. Dec 2008;59(6):1077-9. [Medline].
Smoller BR, Rosen S. Port-wine stains. A disease of altered neural modulation of blood vessels?. Arch Dermatol. Feb 1986;122(2):177-9. [Medline].
Chang CJ, Yu JS, Nelson JS. Confocal microscopy study of neurovascular distribution in facial port wine stains (capillary malformation). J Formos Med Assoc. Jul 2008;107(7):559-66. [Medline].
Vural E, Ramakrishnan J, Cetin N, Buckmiller L, Suen JY, Fan CY. The expression of vascular endothelial growth factor and its receptors in port-wine stains. Otolaryngol Head Neck Surg. Oct 2008;139(4):560-4. [Medline].
Kaji N, Nagase T, Nagase M, Koshima I. Changes in angiogenic gene expression in a case of expanded capillary malformation: does an expanded capillary malformation grow?. Ann Plast Surg. Jun 2005;54(6):645-50. [Medline].
Boon LM, Mulliken JB, Vikkula M. RASA1: variable phenotype with capillary and arteriovenous malformations. Curr Opin Genet Dev. Jun 2005;15(3):265-9. [Medline].
Hershkovitz D, Bergman R, Sprecher E. A novel mutation in RASA1 causes capillary malformation and limb enlargement. Arch Dermatol Res. Aug 2008;300(7):385-8. [Medline].
Hershkovitz D, Bercovich D, Sprecher E, Lapidot M. RASA1 mutations may cause hereditary capillary malformations without arteriovenous malformations. Br J Dermatol. May 2008;158(5):1035-40. [Medline].
Motley RJ, Lanigan SW, Katugampola GA. Videomicroscopy predicts outcome in treatment of port-wine stains. Arch Dermatol. Jul 1997;133(7):921-2. [Medline].
Lanigan SW, Cotterill JA. Psychological disabilities amongst patients with port wine stains. Br J Dermatol. Aug 1989;121(2):209-15. [Medline].
Sheehan DJ, Lesher JL Jr. Pyogenic granuloma arising within a port-wine stain. Cutis. Mar 2004;73(3):175-80. [Medline].
da Silva AD, Silva CA, de Camargo Moraes P, Thomaz LA, Furuse C, de Araújo VC. Recurrent oral pyogenic granuloma in port-wine stain. J Craniofac Surg. Nov 2011;22(6):2356-8. [Medline].
Pratt AG. Birthmarks in infants. AMA Arch Derm Syphilol. Mar 1953;67(3):302-5. [Medline].
Afsar FS, Ortac R. Acquired port-wine stain in a pediatric patient. J Cutan Med Surg. May-Jun 2006;10(3):151-3. [Medline].
Geronemus RG, Ashinoff R. The medical necessity of evaluation and treatment of port-wine stains. J Dermatol Surg Oncol. Jan 1991;17(1):76-9. [Medline].
Maari C, Frieden IJ. Klippel-Trénaunay syndrome: the importance of "geographic stains" in identifying lymphatic disease and risk of complications. J Am Acad Dermatol. Sep 2004;51(3):391-8. [Medline].
Ch'ng S, Tan ST. Facial port-wine stains - clinical stratification and risks of neuro-ocular involvement. J Plast Reconstr Aesthet Surg. Aug 2008;61(8):889-93. [Medline].
Pascual-Castroviejo I, Pascual-Pascual SI, Velazquez-Fragua R, Viano J. Sturge-Weber syndrome: study of 55 patients. Can J Neurol Sci. Jul 2008;35(3):301-7. [Medline].
Huiras EE, Barnes CJ, Eichenfield LF, Pelech AN, Drolet BA. Pulmonary thromboembolism associated with Klippel-Trenaunay syndrome. Pediatrics. Oct 2005;116(4):e596-600. [Medline].
Samimi M, Maruani A, Bertrand P, Arbeille P, Lorette G. Arterial blood flow in limbs with port-wine stains can predict length discrepancy. Br J Dermatol. Jan 2009;160(1):219-20. [Medline].
Toriello HV, Mulliken JB. Accurately renaming macrocephaly-cutis marmorata telangiectatica congenita (M-CMTC) as macrocephaly-capillary malformation (M-CM). Am J Med Genet A. Dec 15 2007;143A(24):3009. [Medline].
Guggisberg D, Hadj-Rabia S, Viney C, et al. Skin markers of occult spinal dysraphism in children: a review of 54 cases. Arch Dermatol. Sep 2004;140(9):1109-15. [Medline].
Tubbs RS, Wellons JC 3rd, Iskandar BJ, Oakes WJ. Isolated flat capillary midline lumbosacral hemangiomas as indicators of occult spinal dysraphism. J Neurosurg. Feb 2004;100(2 Suppl Pediatrics):86-9. [Medline].
Happle R. Phacomatosis pigmentovascularis revisited and reclassified. Arch Dermatol. Mar 2005;141(3):385-8. [Medline].
Lapidoth M, Ben Amitai D, Feinmesser M, Akerman L. Capillary malformation associated with angiolipoma: analysis of 127 consecutive clinic patients. Am J Clin Dermatol. 2008;9(6):389-92. [Medline].
Happle R. Loss of heterozygosity in human skin. J Am Acad Dermatol. Aug 1999;41(2 Pt 1):143-64. [Medline].
Kouba DJ, Yip D, Fincher EF, Moy RL. Topical imiquimod in the treatment of a long-standing capillary malformation. Br J Dermatol. Nov 2007;157(5):1071-2. [Medline].
Faurschou A, Olesen AB, Leonardi-Bee J, Haedersdal M. Lasers or light sources for treating port-wine stains. Cochrane Database Syst Rev. Nov 9 2011;11:CD007152. [Medline].
Kono T, Groff WF, Sakurai H. Treatment of port wine stains with the pulse dye laser. Ann Plast Surg. Apr 2006;56(4):460-3. [Medline].
Sivarajan V, MacKay IR. The relationship between location, color, and vessel structure within capillary vascular malformations. Ann Plast Surg. Oct 2004;53(4):378-81. [Medline].
Jia W, Aguilar G, Verkruysse W, Franco W, Nelson JS. Improvement of port wine stain laser therapy by skin preheating prior to cryogen spray cooling: a numerical simulation. Lasers Surg Med. Feb 2006;38(2):155-62. [Medline].
Phung TL, Oble DA, Jia W, Benjamin LE, Mihm MC Jr, Nelson JS. Can the wound healing response of human skin be modulated after laser treatment and the effects of exposure extended? Implications on the combined use of the pulsed dye laser and a topical angiogenesis inhibitor for treatment of port wine stain birthmarks. Lasers Surg Med. Jan 2008;40(1):1-5. [Medline].
Chang CJ, Hsiao YC, Mihm MC Jr, Nelson JS. Pilot study examining the combined use of pulsed dye laser and topical Imiquimod versus laser alone for treatment of port wine stain birthmarks. Lasers Surg Med. Nov 2008;40(9):605-10. [Medline].
Gu Y, Huang NY, Liang J, Pan YM, Liu FG. [Clinical study of 1949 cases of port wine stains treated with vascular photodynamic therapy (Gu's PDT)]. Ann Dermatol Venereol. Mar 2007;134(3 Pt 1):241-4. [Medline].
Huikeshoven M, Koster PH, de Borgie CA, Beek JF, van Gemert MJ, van der Horst CM. Redarkening of port-wine stains 10 years after pulsed-dye-laser treatment. N Engl J Med. Mar 22 2007;356(12):1235-40. [Medline].
Ozdemir M, Engin B, Mevlitoglu I. Treatment of facial port-wine stains with intense pulsed light: a prospective study. J Cosmet Dermatol. Jun 2008;7(2):127-31. [Medline].
Yang MU, Yaroslavsky AN, Farinelli WA, et al. Long-pulsed neodymium:yttrium-aluminum-garnet laser treatment for port-wine stains. J Am Acad Dermatol. Mar 2005;52(3 Pt 1):480-90. [Medline].
Pence B, Aybey B, Ergenekon G. Outcomes of 532 nm frequency-doubled Nd:YAG laser use in the treatment of port-wine stains. Dermatol Surg. May 2005;31(5):509-17. [Medline].
Huang YC, Ringold TL, Nelson JS, Choi B. Noninvasive blood flow imaging for real-time feedback during laser therapy of port wine stain birthmarks. Lasers Surg Med. Mar 2008;40(3):167-73. [Medline].
Kolkman RG, Mulder MJ, Glade CP, Steenbergen W, van Leeuwen TG. Photoacoustic imaging of port-wine stains. Lasers Surg Med. Mar 2008;40(3):178-82. [Medline].
[Guideline] Shevell M, Ashwal S, Donley D, et al. Practice parameter: evaluation of the child with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society. Neurology. Feb 11 2003;60(3):367-80. [Medline].
Fonder MA, Mamelak AJ, Kazin RA, Cohen BA. Port-wine-stain-associated dermatitis: implications for cutaneous vascular laser therapy. Pediatr Dermatol. Jul-Aug 2007;24(4):376-9. [Medline].
Boukobza M, Enjolras O, Cambra M, Merland J. [Sturge-Weber syndrome. The current neuroradiologic data]. J Radiol. Jul 2000;81(7):765-71. [Medline].
Burrows PE, Laor T, Paltiel H, Robertson RL. Diagnostic imaging in the evaluation of vascular birthmarks. Dermatol Clin. Jul 1998;16(3):455-88. [Medline].
Eerola I, Boon LM, Mulliken JB, et al. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet. Dec 2003;73(6):1240-9. [Medline].
Eubanks LE, McBurney EI. Videomicroscopy of port-wine stains: correlation of location and depth of lesion. J Am Acad Dermatol. Jun 2001;44(6):948-51. [Medline].
Garzon MC, Huang JT, Enjolras O, Frieden IJ. Vascular malformations: Part I. J Am Acad Dermatol. Mar 2007;56(3):353-70; quiz 371-4. [Medline].
Goldman MP, Fitzpatrick RE. Laser treatment of cutaneous vascular lesions. In: Goldman MP, Fitzpatrick RE, eds. Cutaneous Laser Surgery: The Art and Science of Selective Photothermolysis. 2nd ed. Mosby-Year Book: St. Louis, Mo; 1999:37-74.
Goldman MP, Fitzpatrick RE, Ruiz-Esparza J. Treatment of port-wine stains (capillary malformation) with the flashlamp-pumped pulsed dye laser. J Pediatr. Jan 1993;122(1):71-7. [Medline].
Huikeshoven M, Koster PH, de Borgie CA, Beek JF, van Gemert MJ, van der Horst CM. Redarkening of port-wine stains 10 years after pulsed-dye-laser treatment. N Engl J Med. Mar 22 2007;356(12):1235-40. [Medline].
Mazereeuw-Hautier J, Syed S, Harper JI. Bilateral facial capillary malformation associated with eye and brain abnormalities. Arch Dermatol. Aug 2006;142(8):994-8. [Medline].
Mulliken JB. Capillary (port-wine) and other telangiectatic stains. In: Vascular Birthmarks. Portland, Ore: Book News; 1988:170-83.
Requena L, Sangueza OP. Cutaneous vascular anomalies. Part I. Hamartomas, malformations, and dilation of preexisting vessels. J Am Acad Dermatol. Oct 1997;37(4):523-49; quiz 549-52. [Medline].
Selim MM, Kelly KM, Nelson JS, Wendelschafer-Crabb G, Kennedy WR, Zelickson BD. Confocal microscopy study of nerves and blood vessels in untreated and treated port wine stains: preliminary observations. Dermatol Surg. Jun 2004;30(6):892-7. [Medline].
Sivarajan V, Maclaren WM, Mackay IR. The effect of varying pulse duration, wavelength, spot size, and fluence on the response of previously treated capillary vascular malformations to pulsed-dye laser treatment. Ann Plast Surg. Jul 2006;57(1):25-32. [Medline].
Waner M, Suen JY. The treatment of vascular malformations. In: Hemangiomas and Vascular Malformations of the Head and Neck. New York, NY: John Wiley & Sons; 1999:353-66.
Waner M, Suen JY. The natural history of vascular malformations. In: Hemangiomas and Vascular Malformations of the Head and Neck. New York, NY: John Wiley & Sons; 1999:52-62.
Print
